Table 4.
Patient-reported adverse events during the study period
| Baseline [n = 30] | Water [n = 29] | Milk [n = 30] | ||||
|---|---|---|---|---|---|---|
| Adverse event | Grade 1–2 | Grade 3 | Grade 1–2 | Grade 3 | Grade 1–2 | Grade 3 |
| All events | 29 (97) | – | 28 (97) | – | 28 (93) | 2 (6) |
| Reported in ≥ 10% of patients | ||||||
| Nausea | 1 (3) | – | 3 (10) | – | 3 (10) | 1 (3) |
| Diarrhea | 6 (20) | – | 3 (10) | – | 3 (10) | – |
| Constipation | 5 (17) | – | 1 (3) | – | 3 (10) | – |
| Fatigue | 10 (33) | – | 10 (34) | – | 6 (20) | – |
| Pain | 5 (17) | – | 7 (24) | – | 9 (30) | – |
| Rash | 23 (77) | – | 18 (62) | – | 20 (67) | 1 (3) |
| Alopecia | 12 (40) | – | 11 (38) | – | 11 (37) | – |
| Serious adverse event | – | 1 (3%)a | – | – | – | – |
Data are expressed as n (%)
Water = both periods wherein patients used water to take erlotinib, both without and with esomeprazole
Milk = both periods wherein patients used cow’s milk to take erlotinib, both without and with esomeprazole
aSerious adverse event was a spinal fracture that needed hospital admission during which erlotinib was continued